TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, …
( read original story …)


Search your Hotel